AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

ClinicalTrials.gov ID: NCT05683379

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05683379. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).

Study identification

NCT ID: NCT05683379
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: REGENXBIO Inc.; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Duchenne Muscular Dystrophy

Interventions

AAV8 DetectCDx Diagnostic Test

Diagnostic Test

Eligibility (public fields only)

Age range: 0 Years to 25 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 20, 2022 (Actual)
Primary completion: Jun 30, 2026 (Actual)
Completion: Sep 2026 (Estimated)
Last update posted: Jul 7, 2026

2022 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Rare Disease Research	Atlanta	Georgia	30329	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05683379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 7, 2026 · Synced Nov 15, 2026